相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2
Christoph Schliemann et al.
BLOOD (2009)
Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients
Stefanie Sauer et al.
BLOOD (2009)
HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody
Wei Wang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Potent antibody drug conjugates for cancer therapy
Peter D. Senter
CURRENT OPINION IN CHEMICAL BIOLOGY (2009)
Broad-Spectrum Inhibition of Retroviral and Filoviral Particle Release by Tetherin
Nolwenn Jouvenet et al.
JOURNAL OF VIROLOGY (2009)
Comparative immunohistochemistry of L19 and F16 in non-small cell lung cancer and mesothelioma: Two human antibodies investigated in clinical trials in patients with cancer
Marta Pedretti et al.
LUNG CANCER (2009)
HIV-1 Vpu Neutralizes the Antiviral Factor Tetherin/BST-2 by Binding It and Directing Its Beta-TrCP2-Dependent Degradation
Bastien Mangeat et al.
PLOS PATHOGENS (2009)
Interferon-α enhances CD317 expression and the antitumor activity of anti-CD317 monoclonal antibody in renal cell carcinoma xenograft models
Shigeto Kawai et al.
CANCER SCIENCE (2008)
Antibody-Mediated Delivery of Interleukin-2 to the Stroma of Breast Cancer Strongly Enhances the Potency of Chemotherapy
Jessica Marlind et al.
CLINICAL CANCER RESEARCH (2008)
The ties that bind a virus to the cell
Robert P. Kruger
CELL (2008)
Drug therapy: Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma
Bruce D. Cheson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu
Stuart J. D. Neil et al.
NATURE (2008)
Selective Alpha-Particle Mediated Depletion of Tumor Vasculature with Vascular Normalization
Jaspreet Singh Jaggi et al.
PLOS ONE (2007)
Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent
Mark S. Dennis et al.
CANCER RESEARCH (2007)
A chemical proteomics approach for the identification of accessible antigens expressed in human kidney cancer
Vincent Castronovo et al.
MOLECULAR & CELLULAR PROTEOMICS (2006)
Bone marrow stromal cell antigen 2 is a specific marker of type IIFN-producing cells in the naive mouse, but a promiscuous cell surface antigen following IFN stimulation
Amanda L. Blasius et al.
JOURNAL OF IMMUNOLOGY (2006)
Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C
Simon S. Brack et al.
CLINICAL CANCER RESEARCH (2006)
Fibronectin as target for tumor therapy
M Kaspar et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Engineered antibody Fc variants with enhanced effector function
GA Lazar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
The carbohydrate at FcγRIIIa Asn-162 -: an element required for high affinity binding to non-fucosylated IgG glycoforms
C Ferrara et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Antibody targeted drugs as cancer therapeutics
D Schrama et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
In vivo protein biotinylation and sample preparation for the proteomic identification of organ- and disease-specific antigens accessible from the vasculature
Christoph Roesli et al.
NATURE PROTOCOLS (2006)
Divergent immunoglobulin G subclass activity through selective Fc receptor binding
F Nimmerjahn et al.
SCIENCE (2005)
The natural history of a novel, systemic, disseminated model of syngeneic mouse B-cell lymphoma
MJ Passineau et al.
LEUKEMIA & LYMPHOMA (2005)
Identification and relative quantification of membrane proteins by surface biotinylation and two-dimensional peptide mapping
SB Scheurer et al.
PROTEOMICS (2005)
In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment
DA Sipkins et al.
NATURE (2005)
In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature
JN Rybak et al.
NATURE METHODS (2005)
Monoclonal antibody therapy of cancer
GP Adams et al.
NATURE BIOTECHNOLOGY (2005)
Vascular targeting agents as cancer therapeutics
PE Thorpe
CLINICAL CANCER RESEARCH (2004)
Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma
DA Rizzieri et al.
BLOOD (2004)
Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy
P Oh et al.
NATURE (2004)
Selective targeted delivery of TNFα to tumor blood vessels
L Borsi et al.
BLOOD (2003)
Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature
C Halin et al.
NATURE BIOTECHNOLOGY (2002)
Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix
B Carnemolla et al.
BLOOD (2002)
分享论文
